Literature DB >> 707305

Effects of estrogen on human seminiferous tubules: light and electron microscopic analysis.

C C Lu, A Steinberger.   

Abstract

Morphological features of testes from four subjects after long-term treatment with ethinyl-estradiol (1--2 mg daily) and from five non-treated patients with prostatic carcinoma were studied by means of light and electron microscopy. The non-treated seminiferous tubules contained spermatagonia, spermatocytes, spermatids, spermatozoa, and Sertoli cells and showed no apparent morphologic abnormalities. On the other hand, the estrogen-treated testicular tissue contained only Sertoli cells and very few spermatogonia within the seminiferous tubules. The nuclei of Sertoli cells occasionally contained two nucleoli. The nucleolar complex was composed of a fine granular spherical body surrounded by a large granular, reticular network. The cytoplasm of the Sertoli cell contained osmiophilic lipid-like bodies. These lipid-like bodies appeared more pronounced in patients treated with higher doses of estrogen, suggesting a diminution of secretion of Sertoli cell hormone. Blebbing from the outer nuclear membrane appeared to have formed numerous vesicles in the cytoplasm. These vesicles usually contained several membrane-bound granular bodies. In the estrogen-treated testes, there was a marked increase in thickness and infolding of the basement membrane. Two unusual patterns of the basement membrane were observed: one appeared to be a reticular anastomosis, the other, an electron-dense trilayer. The morphological picture of seminiferous tubules from the estrogen-treated subjects appeared to correlate well with the suppressed plasma and testicular levels of testesterone, the undetectable circulating gonadotrophins, and the elevated plasma and testicular levels of estradiol-17 beta reported by Rodriguez-Rigau et al. ('77).

Entities:  

Keywords:  Biology; Cancer; Clinical Research; Comparative Studies; Contraception; Contraceptive Agents, Estrogen--side effects; Contraceptive Agents, Estrogen--therapeutic use; Contraceptive Agents, Female--side effects; Contraceptive Agents, Female--therapeutic use; Contraceptive Agents--side effects; Contraceptive Agents--therapeutic use; Demographic Factors; Ethinyl Estradiol--side effects; Ethinyl Estradiol--therapeutic use; Family Planning; Genitalia; Genitalia, Male; Germ Cells; In Vitro; Longterm Effects; Physiology; Population; Population Dynamics; Research Methodology; Spermatozoa; Studies; Testis; Time Factors; Urogenital System

Mesh:

Substances:

Year:  1978        PMID: 707305     DOI: 10.1002/aja.1001530102

Source DB:  PubMed          Journal:  Am J Anat        ISSN: 0002-9106


  6 in total

1.  Response of the human testis to long-term estrogen treatment: morphology of Sertoli cells, Leydig cells and spermatogonial stem cells.

Authors:  C Schulze
Journal:  Cell Tissue Res       Date:  1988-01       Impact factor: 5.249

2.  An ultrastructural study on the presence of various types of crystals in the infertile human testis.

Authors:  M Kaya; R Türkyilmaz
Journal:  Anat Embryol (Berl)       Date:  1985

3.  The testis in adreno-leukodystrophy.

Authors:  J M Powers; H H Schaumburg
Journal:  Am J Pathol       Date:  1981-01       Impact factor: 4.307

4.  On the expression of H-Y antigen in transsexuals.

Authors:  S Wachtel; R Green; N G Simon; A Reichart; L Cahill; J Hall; D Nakamura; G Wachtel; W Futterweit; S H Biber
Journal:  Arch Sex Behav       Date:  1986-02

Review 5.  Male reproductive cancers and infertility: a mutual relationship.

Authors:  Eva Tvrda; Ashok Agarwal; Nawaf Alkuhaimi
Journal:  Int J Mol Sci       Date:  2015-03-31       Impact factor: 5.923

6.  Histological study on the influence of puberty suppression and hormonal treatment on developing germ cells in transgender women.

Authors:  I de Nie; C L Mulder; A Meißner; Y Schut; E M Holleman; W B van der Sluis; S E Hannema; M den Heijer; J Huirne; A M M van Pelt; N M van Mello
Journal:  Hum Reprod       Date:  2022-01-28       Impact factor: 6.918

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.